Patient Group’s Success Developing Drugs Earns Kudos, Criticism
About 15 years ago, the Cystic Fibrosis Foundation began investing in a biotechnology firm to develop drugs to treat the lung disease. That funding has produced new drugs, but their price tags have spurred criticism of the group, reports The New York Times. Meanwhile, the FDA delays a rule for updating generic drug labeling.